Does Blue Cross Blue Shield of Michigan Cover Liraglutide (Saxenda)?

What Is Liraglutide (Saxenda) and Why Does Insurance Scrutinize It?

Liraglutide 3 mg (Saxenda) is a glucagon-like peptide-1 (GLP-1) receptor agonist injected once daily for chronic weight management. The FDA approved it in December 2014 for adults with a BMI of 30 or greater, or a BMI of 27 or greater accompanied by at least one weight-related condition such as type 2 diabetes, hypertension, or dyslipidemia. [1]

Insurance carriers apply close scrutiny to anti-obesity medications because their monthly list prices run high. Saxenda's wholesale acquisition cost is approximately $1,400 per month without discounts. That price point pushes payers to require clinical justification before approving coverage.

The Clinical Evidence Behind the Coverage Decision

The SCALE Obesity and Prediabetes trial (N=3,731) demonstrated that liraglutide 3 mg produced a mean weight loss of 8.4% at 56 weeks, compared with 2.5% in the placebo group (P<0.001). [2] Roughly 63% of liraglutide-treated participants lost at least 5% of body weight versus 27% on placebo. [2]

A second SCALE trial, SCALE Diabetes (N=846), focused on adults with type 2 diabetes and showed a mean weight loss of 6.0% at 56 weeks versus 2.0% with placebo (P<0.001). [3] Payers sometimes cite this trial when evaluating whether a patient with diabetes meets criteria under a lower BMI threshold.

The American Association of Clinical Endocrinology (AACE) 2022 obesity guidelines recommend GLP-1 receptor agonists, including liraglutide, as first-line adjunct pharmacotherapy for adults with BMI 30 or greater or BMI 27 or greater with a weight-related comorbidity. [4]

How Saxenda Differs from Ozempic and Wegovy on Coverage

Liraglutide 3 mg (Saxenda) and semaglutide 2.4 mg (Wegovy) are both GLP-1 agonists approved specifically for weight management, while semaglutide 1 mg/0.5 mg (Ozempic) is approved only for type 2 diabetes. BCBS Michigan formularies typically treat these as distinct products in different coverage tiers. Saxenda has been on the market longer, so payer coverage criteria are more established, but it is often placed on a less favorable tier than older generics. [5]

BCBS Michigan Plan Types and How They Differ

Blue Cross Blue Shield of Michigan operates several distinct plan lines. Coverage rules for Saxenda vary across them.

Blue Cross Commercial (PPO and HMO Products)

Most BCBS Michigan commercial group plans include Saxenda on a Specialty or Tier 3/4 formulary position. Prior authorization is required. The standard commercial coverage criteria typically include:

• BMI 30 or greater, OR BMI 27 or greater with hypertension, dyslipidemia, type 2 diabetes, or obstructive sleep apnea documented in the chart
• Documentation that the patient has attempted a structured diet and exercise program for at least 6 months with inadequate weight loss
• Prescriber attestation that liraglutide is being used as an adjunct to a reduced-calorie diet and increased physical activity
• No concurrent use of another prescription weight-loss agent

The FDA label explicitly requires liraglutide to be used alongside dietary modification and physical activity, so BCBS Michigan's documentation requirement mirrors the approved indication. [1]

Blue Care Network (HMO)

Blue Care Network, the HMO subsidiary of BCBS Michigan, uses a separate formulary. Saxenda may appear on a different tier than on the PPO formulary, and step therapy requirements can be stricter. Some BCN plans require a documented 3-month trial of orlistat (Xenical/Alli) before approving Saxenda. Confirm current tier placement by calling the number on the back of your BCN member card or using the BCN drug search tool at bcbsm.com.

Medicare Advantage and Part D

Federal law historically prohibited Medicare Part D plans from covering drugs prescribed solely for weight loss, under the Social Security Act exclusion. [6] As of mid-2025, the Preventing ACES Act and related legislative proposals have not yet fully lifted that restriction for all Part D plans. Some BCBS Medicare Advantage plans cover Saxenda when it is prescribed for a comorbidity (such as type 2 diabetes managed with liraglutide at a lower dose). Check your specific plan's Evidence of Coverage document for 2025 because plan formularies update annually. [6]

Medicaid (Healthy Michigan Plan)

The Michigan Department of Health and Human Services Medicaid program (Healthy Michigan Plan) evaluates anti-obesity medications separately from commercial plans. Coverage for Saxenda under Healthy Michigan Plan is limited and typically requires prior authorization with strict clinical criteria. Contact Michigan Medicaid directly at 1-800-642-3195 for the most current preferred drug list status.

Prior Authorization Criteria: What Your Doctor Must Document

Prior authorization for Saxenda under BCBS Michigan requires a formal clinical submission. Missing a single element commonly triggers an automatic denial.

Required Clinical Elements

Your physician's office typically needs to submit:

1. Current weight and height with calculated BMI (BMI 30 or BMI 27 with comorbidity)
2. Diagnosis codes for the qualifying comorbidity if BMI is 27 to 29.9 (ICD-10 codes E11.x for type 2 diabetes, I10 for hypertension, E78.x for dyslipidemia, or G47.33 for obstructive sleep apnea)
3. A note documenting at least 6 months of structured diet and exercise intervention, with dates
4. The prescriber's NPI and specialty (endocrinology, internal medicine, or obesity medicine preferred)
5. Documentation that the patient is not pregnant and has no personal or family history of medullary thyroid carcinoma or MEN2 syndrome (both listed as contraindications in the FDA label) [1]

Step Therapy: The Orlistat Hurdle

Some BCBS Michigan commercial plans apply a step therapy requirement that mandates a trial of orlistat 120 mg three times daily before approving Saxenda. Orlistat is the only FDA-approved weight-loss agent available generically and at lower cost. [7] If your plan has this requirement, your physician must document the orlistat trial, the duration, the weight-loss result, and the reason for discontinuation if applicable (gastrointestinal side effects are the most common reason). A clinical exception to step therapy can be requested when orlistat is contraindicated or causes documented adverse effects.

Continuity Authorization (Re-Authorization)

Initial approval typically covers 90 days. Continued authorization requires evidence of meaningful response, defined by most BCBS Michigan policies as at least 4% body weight loss at 16 weeks of treatment. This threshold aligns with the FDA label's recommendation that providers evaluate response at 16 weeks and consider discontinuation if a patient has not lost at least 4% of baseline body weight. [1] Bring your 16-week weight to every follow-up visit and document it in the chart.

How to Calculate Your Out-of-Pocket Cost

Even with coverage, Saxenda carries meaningful cost-sharing.

Tier Placement and Copay Math

On a typical BCBS Michigan commercial plan, Saxenda sits at Tier 3 or Tier 4. A Tier 3 specialty copay after deductible often runs $75, $100 for a 30-day supply. Before the deductible is met, you pay the plan's contracted rate, which can be $400, $700 per month even with insurance negotiated pricing. If your plan has a $2,000 individual deductible, expect full cost-sharing for the first one to three months of the year.

Novo Nordisk Savings Programs

Novo Nordisk offers a Saxenda savings card for commercially insured patients who are not using government insurance (Medicare, Medicaid, TRICARE). Eligible patients may pay as little as $25 for a 30-day supply for up to 24 months, subject to a monthly cap of $200 in savings. [8] This program does not apply to Medicare or Medicaid beneficiaries.

Specialty Pharmacy Routing

BCBS Michigan may require you to fill Saxenda at a preferred specialty pharmacy rather than a retail chain. CVS Specialty and Walgreens Specialty are common preferred vendors on BCBS Michigan plans. Filling at a non-preferred specialty pharmacy can double your cost-sharing, so confirm preferred pharmacy status before the first fill.

What to Do If BCBS Michigan Denies Your Saxenda Claim

Denials fall into two categories: prior authorization denial (before dispensing) and claim denial (after dispensing at the pharmacy).

Step 1: Request the Denial Reason in Writing

BCBS Michigan is required under Michigan Insurance Code and the ACA to provide a written explanation of any adverse coverage decision. The denial letter will cite the specific criteria not met. Common denial reasons include insufficient BMI documentation, incomplete step therapy, or a plan exclusion for weight-loss drugs.

Step 2: File an Internal Appeal

You have the right to file an internal (first-level) appeal within 180 days of the denial. Ask your prescriber to submit a peer-to-peer review call with the BCBS Michigan medical director. Studies show that peer-to-peer calls resolve a meaningful percentage of prior-authorization denials before a formal appeal is needed. [9] Submit all clinical notes, weight trend data, comorbidity documentation, and any relevant published guidelines supporting Saxenda's use.

Step 3: External Appeal Through the Michigan DIFS

If the internal appeal fails, Michigan law allows you to request an external independent review through the Michigan Department of Insurance and Financial Services (DIFS). The external reviewer must be a board-certified clinician with no affiliation to BCBS Michigan. External appeal decisions are binding on the insurer for most plan types. [10]

Step 4: Medical Exception Request

A medical exception (also called a formulary exception) allows coverage of a non-formulary drug or waiver of step therapy when standard alternatives are medically contraindicated. Your physician submits a letter of medical necessity explaining why orlistat or a lower-tier alternative cannot be used. The AACE 2022 guidelines and the SCALE trial data are appropriate supporting documents for that letter. [4]

The Prescriber's Role in Securing Coverage

The prescriber's documentation quality is the single largest determinant of prior-authorization success.

Specialty Matters

BCBS Michigan's coverage criteria do not formally restrict prescribers by specialty for Saxenda, but submissions from endocrinologists and board-certified obesity medicine physicians carry more clinical weight in peer-to-peer reviews. The American Board of Obesity Medicine (ABOM) certifies physicians in obesity medicine; a prescriber with ABOM certification can reference that credential when speaking with a BCBS medical reviewer. [11]

Objective Data the Physician Should Include

Include in the chart note: serial weight measurements over at least 6 months, documentation of the structured intervention tried, any comorbidity lab values (HbA1c, fasting lipid panel, blood pressure readings), and a statement that the patient understands the drug must be used with diet and exercise modification per the FDA label. [1] A chart note that reads "patient requests weight-loss medication" is not sufficient. A note that documents a 6-month supervised program, a starting weight of 248 lb, a current weight of 241 lb (2.8% loss), persistent hypertension with BP averaging 148/92 mmHg, and a BMI of 31.4 gives the BCBS medical reviewer the specific data needed to approve the claim.

Documenting Contraindications to Step Therapy Alternatives

If the plan requires orlistat first, document any contraindication (malabsorption syndrome, cholestasis) or prior adverse effect (severe steatorrhea requiring hospitalization) with dates and clinical details. Vague statements like "patient cannot tolerate orlistat" are routinely rejected. Specific chart entries, pharmacy records showing a dispensed orlistat prescription, and a dated note describing the adverse event are far more persuasive.

Liraglutide vs. Other GLP-1 Options: Does the Insurance Math Change?

Some patients ask whether switching from Saxenda to a different GLP-1 agonist changes their coverage picture with BCBS Michigan.

Semaglutide 2.4 mg (Wegovy)

Wegovy received FDA approval in June 2021 for chronic weight management. [12] The STEP-1 trial (N=1,961) showed a mean weight loss of 14.9% at 68 weeks with semaglutide 2.4 mg versus 2.4% with placebo (P<0.001). [13] BCBS Michigan commercial plans cover Wegovy with similar prior authorization criteria to Saxenda, but formulary tier placement and step therapy requirements differ by plan. Some BCBS Michigan plans have moved Saxenda to a preferred tier over Wegovy because of negotiated rebates, making Saxenda the lower-cost option for the patient even though Wegovy shows greater average weight loss.

Tirzepatide 15 mg (Zepbound)

Tirzepatide (Zepbound), a dual GIP/GLP-1 agonist, received FDA approval for weight management in November 2023. [14] The SURMOUNT-1 trial (N=2,539) showed a mean weight loss of 20.9% at 72 weeks with tirzepatide 15 mg versus 3.1% with placebo (P<0.001). [15] BCBS Michigan commercial formulary placement for Zepbound is evolving in 2025. Some plans exclude it while covering Saxenda; others have added it as a preferred option. Confirming formulary status before prescribing saves the patient and pharmacy staff time.

Practical Checklist Before Submitting the Prior Authorization

Use this checklist to confirm your submission is complete before your physician's office sends it to BCBS Michigan.

• Current height, weight, and calculated BMI documented in chart note dated within 90 days
• ICD-10 diagnosis code for obesity (E66.01 for morbid obesity due to excess calories, or E66.09 for other obesity) plus comorbidity code if BMI is 27 to 29.9
• 6-month diet and exercise program documented with start date, modality, and result
• Step therapy element: orlistat trial documented or contraindication letter included
• Prescriber's NPI, DEA number, and office contact for peer-to-peer callback
• Patient's date of birth, member ID, and group number on every page of the submission
• FDA label contraindication screen: no personal or family history of medullary thyroid carcinoma or MEN2 syndrome confirmed in note [1]
• Signed patient acknowledgment that drug is to be used with diet and physical activity

Key Numbers to Know Before You Call BCBS Michigan

BCBS Michigan prior authorization line: 1-800-437-3803 (commercial) or the number on the back of your insurance card. Standard prior authorization turnaround is 3 business days for non-urgent requests; urgent requests require a response within 72 hours under Michigan law. A denied prior authorization can be appealed within 180 days. The external DIFS appeal fee is waived for patients. [10]

For coverage verification, ask the BCBS representative specifically: "Is liraglutide 3 mg (Saxenda, NDC 00169-4060-12) covered on my formulary, what tier, and what are the prior authorization criteria?" Having the NDC number ready speeds the lookup.